

| Catalog No. | HB941156 |
|---|---|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| Host species | Human |
| Clonality | Monoclonal |
| Isotype | IgG |
| Clone ID | MW02 |
| Target | L-VEGF, N-VEGF, VEGF, VEGFA, VPF, Vascular endothelial growth factor A, long form, Vascular permeability factor |
| Endotoxin level | < 10 EU/mg |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P15692 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | MW02 |
| Background | Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin). 1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969 |
| References | 1. Pitiot A, et al. Alternative Routes of Administration for Therapeutic Antibodies-State of the Art. Antibodies (Basel). 2022 Aug 26;11(3):56. [HB941156] |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human VEGFA (MW02)




Contact us for custom quotes, bulk requests and any other issues.
Mail: [email protected]


+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский